Related references
Note: Only part of the references are listed.Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models
Meenal Datta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy
Francesco De Sanctis et al.
SEMINARS IN IMMUNOPATHOLOGY (2023)
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer
Geny Piro et al.
BRITISH JOURNAL OF CANCER (2023)
Role of chemokines in the crosstalk between tumor and tumor-associated macrophages
Rui Qin et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2023)
Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
Zhi-Jian Han et al.
MOLECULES (2022)
Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition
Rohit Rao et al.
NEURO-ONCOLOGY (2022)
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
Klaire Yixin Fjaestad et al.
ONCOGENE (2022)
The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells
Yanning Xu et al.
SCIENTIFIC REPORTS (2022)
Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity
Nicola Tumino et al.
FRONTIERS IN IMMUNOLOGY (2022)
Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment
May Wathone Oo et al.
JCI INSIGHT (2022)
Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
Paola Allavena et al.
FRONTIERS IN ONCOLOGY (2022)
High Expression of CSF-1R Predicts Poor Prognosis and CSF-1Rhigh Tumor-Associated Macrophages Inhibit Anti-Tumor Immunity in Colon Adenocarcinoma
Xingchao Wang et al.
FRONTIERS IN ONCOLOGY (2022)
The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity
Md Nabiul Hasan et al.
CANCERS (2022)
Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
Izabela Sieminska et al.
FRONTIERS IN ONCOLOGY (2022)
A brief glimpse of a tangled web in a small world: Tumor microenvironment
Iman M. Talaat et al.
FRONTIERS IN MEDICINE (2022)
A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
C. Guo et al.
ANNALS OF ONCOLOGY (2022)
Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment
Anik Pramanik et al.
LIFE SCIENCES (2022)
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Yuze Wu et al.
MOLECULAR CANCER (2022)
Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses
Dylan T. Ammons et al.
CANCER RESEARCH COMMUNICATIONS (2022)
TRIPLE-DRUG ORAL IMMUNOTHERAPY TARGETING MYELOID CELLS FOR TREATMENT OF METASTATIC OSTEOSARCOMA EVALUATED IN SPONTANEOUS CANINE MODEL
Cheryl London et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Tryptophan-kynurenine ratio as a biomarker of bladder cancer
Sze Han Lee et al.
BJU INTERNATIONAL (2021)
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
Kristen Fousek et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Takeshi Hatanaka et al.
PHARMACEUTICALS (2021)
Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice
Cameron MacDonald et al.
CELLULAR IMMUNOLOGY (2021)
Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through β-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades
Mingyue Cao et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer
Rhynelle S. Dmello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
Robert J. Cherney et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells
Douglas T. Fearon et al.
BRITISH JOURNAL OF CANCER (2021)
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas
Na Niu et al.
HUMAN PATHOLOGY (2021)
Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer
Martina Mandarano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Advances in Pancreatic Ductal Adenocarcinoma Treatment
Eric M. Anderson et al.
CANCERS (2021)
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
Jen-Shin Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment
Guanxi Qiao et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer
Tiffany R. Emmons et al.
CANCER IMMUNOLOGY RESEARCH (2021)
The Role of Macrophages in Cancer Development and Therapy
Ewa Cendrowicz et al.
CANCERS (2021)
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
Nicole K. Yun et al.
CANCERS (2021)
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
Lori J. Goldstein et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
Maosen Xu et al.
CELL PROLIFERATION (2021)
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors
Xiuhua Lu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Pedro Bule et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Neutrophil extracellular traps in cancer: not only catching microbes
Livia Ronchetti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Macrophages as a weapon in anticancer cellular immunotherapy
Dmitry Aminin et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2021)
L-Tryptophan activates the aryl hydrocarbon receptor and induces cell cycle arrest in porcine trophectoderm cells
Kang Xu et al.
THERIOGENOLOGY (2021)
The Recruitment of Neutrophils to the Tumor Microenvironment Is Regulated by Multiple Mediators
Shuvasree SenGupta et al.
FRONTIERS IN IMMUNOLOGY (2021)
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment
Jiakang Jin et al.
FRONTIERS IN ONCOLOGY (2021)
At the bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer
Gary D. Luker et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2021)
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present
William A. Denny et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Filippo Veglia et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Marcus Noel et al.
INVESTIGATIONAL NEW DRUGS (2020)
Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Jonathan G. Hiller et al.
CLINICAL CANCER RESEARCH (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Sarah Greene et al.
CLINICAL CANCER RESEARCH (2020)
Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead
Jinxin Che et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Myeloid-derived suppressor cells-new and exciting players in lung cancer
Zhenzhen Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A Small Molecule CCR2 Antagonist Depletes Tumor Macrophages and Synergizes with Anti-PD-1 in a Murine Model of Cutaneous T -Cell Lymphoma (CTCL)
Xuesong Wu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma
Dan A. Erkes et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional
Antonella Borgatti et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2020)
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Andrew M. K. Law et al.
CELLS (2020)
T Cell Dysfunction and Exhaustion in Cancer
Zhen Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non-Small Cell Lung Cancer
Elodie Lauret Marie Joseph et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
Brooke Benner et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Alireza Labani-Motlagh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C. Yuen et al.
NATURE MEDICINE (2020)
MDSC subtypes and CD39 expression on CD8+T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC
Jiae Koh et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
Dual roles of neutrophils in metastatic colonization are governed by the host NK cell status
Peishan Li et al.
NATURE COMMUNICATIONS (2020)
Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment
Vitaliy Davidov et al.
FRONTIERS IN IMMUNOLOGY (2020)
Metabolic reprograming of tumor-associated macrophages
Abhishek Puthenveetil et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells
Monika Barathova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CXCR1 AND CXCR2 CHEMOKINE RECEPTOR AGONISTS PRODUCED BY TUMORS INDUCE NEUTROPHIL EXTRACELLULAR TRAPS THAT INTERFERE WITH IMMUNE CYTOTOXICITY
Alvaro Teijeira et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The updated landscape of tumor microenvironment and drug repurposing
Ming-Zhu Jin et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek et al.
NATURE REVIEWS IMMUNOLOGY (2020)
TIPE1 suppresses osteosarcoma tumor growth by regulating macrophage infiltration
P. Chen et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
Luca Cassetta et al.
CANCER CELL (2019)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models
Manman Deng et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C. A. Gomez-Roca et al.
ANNALS OF ONCOLOGY (2019)
Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents
Kanae Yumimoto et al.
CANCER SCIENCE (2019)
The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment
Daniel P. Regan et al.
JOURNAL OF IMMUNOLOGY (2019)
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment
Xing-Yu Mu et al.
MOLECULAR IMMUNOLOGY (2019)
Targeting Tumor-Associated Macrophages in Cancer
Paulina Pathria et al.
TRENDS IN IMMUNOLOGY (2019)
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
Yuxin Lin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Tumour-associated neutrophils in patients with cancer
Merav E. Shaul et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI
Hye Rim Cho et al.
SCIENTIFIC REPORTS (2019)
Neutrophil extracellular traps induced by activated platelets contribute to procoagulant activity in patients with colorectal cancer
Yan Zhang et al.
THROMBOSIS RESEARCH (2019)
Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression
Ignacio Inigo-Marco et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy
Maria Teresa Masucci et al.
FRONTIERS IN ONCOLOGY (2019)
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Christopher Groth et al.
BRITISH JOURNAL OF CANCER (2019)
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis
Brian W. Labadie et al.
CLINICAL CANCER RESEARCH (2019)
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
Yongkun Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
Mohamed A. ElTanbouly et al.
SEMINARS IN IMMUNOLOGY (2019)
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Julia Kargl et al.
JCI INSIGHT (2019)
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
Robert Wesolowski et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Unmasking the Many Faces of Tumor-Associated Neutrophils and Macrophages: Considerations for Targeting Innate Immune Cells in Cancer
Tyler Keeley et al.
TRENDS IN CANCER (2019)
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Lillian Sun et al.
JCI INSIGHT (2019)
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report
Ivana N. Micallef et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer
Fangxuan Li et al.
CANCER BIOLOGY & THERAPY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor-Yue Tan et al.
MOLECULAR CANCER (2018)
Third generation EGFR TKIs: current data and future directions
Chee-Seng Tan et al.
MOLECULAR CANCER (2018)
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype
Juliana B. Candido et al.
CELL REPORTS (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer
Dung Le et al.
CANCER RESEARCH (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer
Julie G. Grossman et al.
ONCOIMMUNOLOGY (2018)
Unique pattern of neutrophil migration and function during tumor progression
Sima Patel et al.
NATURE IMMUNOLOGY (2018)
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Emile J. Clappaert et al.
FRONTIERS IN IMMUNOLOGY (2018)
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Takefumi Komiya et al.
FRONTIERS IN ONCOLOGY (2018)
The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI
Thang Thanh Phan et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2018)
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Jan P. Boettcher et al.
TRENDS IN CANCER (2018)
New checkpoints in cancer immunotherapy
Ling Ni et al.
IMMUNOLOGICAL REVIEWS (2017)
IDO1: An important immunotherapy target in cancer treatment
Fangxuan Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas
D. Yan et al.
ONCOGENE (2017)
Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer
Keehoon Jung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
TARGETED ONCOLOGY (2017)
Yin-yang regulating effects of cancer-associated genes, proteins, and cells: An ancient Chinese concept in vogue in modern cancer research
Shuyong Wei
BIOSCIENCE TRENDS (2017)
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Xueli Nan et al.
ONCOTARGET (2017)
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
Daria Marley Kemp et al.
ONCOTARGET (2017)
Multiple anti-tumor effects of Reparixin on thyroid cancer
Federica Liotti et al.
ONCOTARGET (2017)
Why isn't the angiotensin type 1 receptor a target in cancer?
Gavin P. Vinson
ONCOTARGET (2017)
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Helen Ha et al.
THERANOSTICS (2017)
From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
Amal Kamal Abdel-Aziz et al.
FRONTIERS IN PHARMACOLOGY (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer
Wenbo Yao et al.
EBIOMEDICINE (2017)
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
Amy Barone et al.
CLINICAL CANCER RESEARCH (2017)
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer
Anne F. Schott et al.
CLINICAL CANCER RESEARCH (2017)
Targeting tumor associated myeloid cells with CCR2 inhibitor PF-04136309 enhances gemcitabine/paclitaxel and doxorubicin anti-tumor activity
Sasha Farina et al.
CANCER RESEARCH (2017)
Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap
Evgeniy B. Eruslanov et al.
TRENDS IN CANCER (2017)
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Nicholas Butowski et al.
NEURO-ONCOLOGY (2016)
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
Colin W. Steele et al.
CANCER CELL (2016)
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Sunitinib: the antiangiogenic effects and beyond
Zhonglin Hao et al.
ONCOTARGETS AND THERAPY (2016)
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte et al.
NATURE COMMUNICATIONS (2016)
Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma
Ludovic Jean Wrobel et al.
ONCOTARGET (2016)
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
Cara C. Schafer et al.
ONCOTARGET (2016)
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy
Rikke B. Holmgaard et al.
ONCOIMMUNOLOGY (2016)
Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice
Tao Liu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Bastian von Tresckow et al.
CLINICAL CANCER RESEARCH (2015)
Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC).
Andrea Wang-Gillam et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Transcriptional regulation of myeloid-derived suppressor cells
Thomas Condamine et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2015)
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
Philippe A. Cassier et al.
LANCET ONCOLOGY (2015)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges
Maria Vela et al.
FRONTIERS IN IMMUNOLOGY (2015)
β-adrenergic receptor signaling in prostate cancer
Peder Rustoen Braadland et al.
FRONTIERS IN ONCOLOGY (2015)
Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist
David J. Nicholls et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
CSF-1R Expression in Tumor-Associated Macrophages Is Associated With Worse Prognosis in Classical Hodgkin Lymphoma
Young Wha Koh et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists
David W. Porter et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
Stephen Mok et al.
CANCER RESEARCH (2014)
Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)/SV40Tag mouse model of breast cancer
J. L. Steiner et al.
CYTOKINE (2014)
Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells
Rebecca K. Martin et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
Hui-Yen Chuang et al.
PLOS ONE (2014)
CSF-1 Receptor Signaling in Myeloid Cells
E. Richard Stanley et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Tissue-Infiltrating Neutrophils Constitute the Major In Vivo Source of Angiogenesis-Inducing MMP-9 in the Tumor Microenvironment
Elena I. Deryugina et al.
NEOPLASIA (2014)
CXCL12-CXCR4 Promotes Proliferation and Invasion of Pancreatic Cancer Cells
Bo Shen et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
Roniel Cabrera et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Li Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer
Galina V. Shurin et al.
CANCER MICROENVIRONMENT (2013)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Tumor-associated neutrophils: friend or foe?
Zvi G. Fridlender et al.
CARCINOGENESIS (2012)
Bindarit An anti-inflammatory small molecule that modulates the NF kappa B pathway
Eugenio Mora et al.
CELL CYCLE (2012)
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
Massimo Zollo et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression
H. Piccard et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation
Antonio Citro et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2012)
Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice
Je-In Youn et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells
Sara M. Centuori et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature
Qiong-wen Zhang et al.
PLOS ONE (2012)
CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial
Craig H. Moskowitz et al.
BLOOD (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Serum Tryptophan and Kynurenine Concentrations as Parameters for Indoleamine 2,3-Dioxygenase Activity in Patients With Endometrial, Ovarian, and Vulvar Cancer
Renske A. de Jong et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Xinmei Zhu et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Alfredo Carrato Mena et al.
ANTI-CANCER DRUGS (2010)
The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer
Erica K. Sloan et al.
CANCER RESEARCH (2010)
Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
Kiavash Movahedi et al.
CANCER RESEARCH (2010)
Myeloid-derived suppressor cell heterogeneity and subset definition
Elisa Peranzoni et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Yuzo Suzuki et al.
LUNG CANCER (2010)
High Expression of Macrophage Colony-Stimulating Factor-1 Receptor in Peritumoral Liver Tissue Is Associated with Poor Outcome in Hepatocellular Carcinoma After Curative Resection
Jin-Bin Jia et al.
ONCOLOGIST (2010)
Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma
Inigo Espinosa et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Chemoattractant Signaling between Tumor Cells and Macrophages Regulates Cancer Cell Migration, Metastasis and Neovascularization
Chad E. Green et al.
PLOS ONE (2009)
Tyrosine Kinase Inhibitors in Veterinary Medicine
Cheryl A. London
TOPICS IN COMPANION ANIMAL MEDICINE (2009)
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis
Li Yang et al.
CANCER CELL (2008)
Immune surveillance: a balance between protumor and antitumor immunity
Suzanne Ostrand-Rosenberg
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Subsets of myeloid-derived suppressor cells in tumor-bearing mice
Je-In Youn et al.
JOURNAL OF IMMUNOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Tumor-associated macrophages press the angiogenic switch in breast cancer
Elaine Y. Lin et al.
CANCER RESEARCH (2007)
G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells
Junko Yoshida et al.
BIOCHEMICAL PHARMACOLOGY (2007)
B7-H3 and B7-H4 expression in non-small-cell lung cancer
Yuping Sun et al.
LUNG CANCER (2006)
Colony-stimulating factor-1 in immunity and inflammation
V Chitu et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors
M Allegretti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production
P Allavena et al.
CANCER RESEARCH (2005)
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8
H Schaider et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers
C Bizzarri et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors
AS Haqqani et al.
NEOPLASIA (2000)
Share Paper
